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Abstract
A goal of oncology is the individualization of patient
care to optimize therapeutic responses and minimize
toxicities. Achieving this will require noninvasive,
quantifiable, and early markers of tumor response.
Preclinical data from xenografted tumors using a vari-
ety of antitumor therapies have shown that magnetic
resonance imaging (MRI)–measured mobility of tissue
water (apparent diffusion coefficient of water, or ADCw)
is a biomarker presaging cell death in the tumor. This
communication tests the hypothesis that changes in
water mobility will quantitatively presage tumor re-
sponses in patients with metastatic liver lesions from
breast cancer. A total of 13 patients with metastatic
breast cancer and 60measurable liver lesionsweremon-
itored by diffusionMRI after initiation of new courses of
chemotherapy. MR images were obtained prior to, and
at 4, 11, and 39 days following the initiation of therapy
for determination of volumes and ADCw values. The
data indicate that diffusion MRI can predict response
by 4 or 11 days after commencement of therapy, de-
pending on the analytic method. The highest concord-
ance was observed in tumor lesions that were less
than 8 cm3 in volumeat presentation. These results sug-
gest that diffusion MRI can be useful to predict the re-
sponse of liver metastases to effective chemotherapy.
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Introduction
Breast cancer is the most common life-threatening malig-
nancy in women. Metastatic disease is rarely curative de-
spite new therapies and improvements in diagnostics. The
selection of systemic treatment is based on the aggressive-
ness of the cancer, the patient’s comorbidities, and the
response rates and toxicities associated with each therapy.
Most patients with metastatic breast cancer will receive
numerous antitumor therapies in an effort to palliate symp-
toms and prolong life. Thus, preservation of quality of life—
and not solely response rates—has become an important
determinant in choosing therapies. Response rates to var-
ious antitumor regimens range from 10% to 70%, depending of
the number of prior therapies, interval from initial diagnosis,
adjuvant therapy received, and unknown individual character-
istics of the tumor. Thus, predicting a patient’s response to a
particular therapy is difficult. Typically, oncologists empirically
initiate therapies based on known response rates from the
literature and then follow the patients closely for evidence of
response or disease progression based on signs, symptoms,
and/or objective radiographic measures of tumor size. Because
of the inherent insensitivity of standard radiographic tools to
accurately measure changes in tumor volume, radiographic
studies are usually repeated on 3- to 6-month intervals for
monitoring responses. For patients with aggressive disease
involving vital visceral organs, months of ineffective therapy
can lead to permanent and irreversible losses in quality of life,
performance status, and early mortality. Thus, an early, non-
invasive, and reproducible method to determine a tumor’s
responsiveness to a particular antitumor therapy would greatly
benefit these patients. Responders would be continued on
successful therapy, and nonresponders would be discontinued
from ineffective and toxic therapy prior to disease progression
and loss of performance status.
Several MRI modalities have been explored in various
cancer models for the early detection of therapy response.
T2-weighted imaging has been explored to monitor response in
pancreatic cancer [1]; T1 (U) imaging has been used to assess
treatment in brain tumors [2]; dynamic contract-enhanced
(DCE) imaging has been used to asses response to cytotoxic
and cytostatic therapies (reviewed in Ref. [3]); and 1H magnetic
resonance spectroscopy has been used to detect changes in
tumor lactate levels as early indicators of response [4].
Conventional MRI is a sensitive and specific indicator of
metastatic disease to the liver [18]. The validity of MRI for
lesion volume (LV) measurements and quantitation of re-
sponse to chemotherapy has been established [19–21].
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Pathologic correlation studies have established the histolog-
ic basis of variable appearances of hepatic metastases on
conventional MR images [22]. The use of both T1- and T2-
weighted sequences can identify metastases, in spite of
variable T1 and T2 of the metastases relative to normal liver
tissue. The use of both moderately and heavily T2-weighted
images provides high specificity for the identification of
common benign lesions, such as cysts and hemangiomas
[23,24,25]. These benign lesions can thus be identified and
excluded from quantitative diffusion measurements because
of their markedly higher pretreatment apparent diffusion
coefficient of water (ADCw) [26].
In recent years, the ADCw, as measured by diffusion-
weighted magnetic resonance imaging (DWMRI), has
emerged as a novel indicator of tumor response to therapy.
DWMRI is a noninvasive imaging technique that measures
the mobility of water in tissues. Generally, cells restrict water
mobility and, hence, as cell volumes decrease in response
to therapy, there is an increase in the ADCw. In preclinical
models, there is abundant evidence that the ADCw in tumors
increases early in response to successful therapies. This
has been shown in sarcoma, glioma, and breast carci-
noma xenografts treated with cytotoxic chemotherapies,
cytostatic chemotherapies, radiation therapy, and gene ther-
apies [5–11]. Previous work by our group has demonstrated
this effect in breast [12] and prostate [13] cancer xenografts
treated with taxanes. Treatments that caused cells to shrink
led to early increases in ADCw that were predictive of the
ultimate tumor response. It is tempting to extrapolate that
the therapy-induced increases in ADCw are due to cell
shrinkage, although the exact mechanisms have not been
determined [14]. Notably, cell shrinkage occurs early during
the apoptotic program [16]. Thus, it has been hypothesized
that apoptosis-induced cell shrinkage leads to increased
extracellular volume. Because water is not as diffusionally
restricted in the extracellular space, a decrease in cell vol-
ume fraction (i.e., intracellular water) will result in an overall
increase in the ADCw [12]. Because of the strength of these
preclinical data, clinical trials have begun to examine the
effectiveness of the ADCw as an early surrogate marker for
therapy response, particularly in brain tumors [15,16].
This pilot trial examined the change in ADCw of liver
metastases in patients after initiation of new chemotherapy
regimens. Despite the motion problems inherent in visceral
imaging, we have chosen to image liver metastases be-
cause: 1) the liver is more amenable to MRI compared to
the lungs; (2) many other tumor types metastasize common-
ly to the liver (e.g., gastrointestinal carcinomas, lung can-
cers, and melanomas); and (3) patients with liver metastases
typically have a poor prognosis compared to patients with
nonvisceral metastases and thus would benefit most from
early predictors of response.
This communication tests the hypotheses that: (A)
patients with objective clinical responses will have early
increases in the ADCw of their lesions, and (B) that the
magnitude of change in ADCw will predict the magnitude of
objective response. Our results are consistent with both
hypotheses being true. Hence, changes in the ADCw may
improve the treatment of patients by predicting antitumor
responses early during the course of a new therapy.
Materials and Methods
Participant Selection
Patients were recruited from the clinics of the Arizona
Cancer Center and provided voluntary informed consent.
Patients eligible for this study met the following criteria:
histologically confirmed metastatic breast cancer with a
minimum of one liver metastases measuring greater than 1
cm in diameter, measurable in at least two dimensions;
Karnofsky performance status (KPS) z 70%; nonpregnant
state; at least 18 years of age; and scheduled to initiate a
new chemotherapy regimen for their metastatic disease.
MRI
Patients underwent their first MRI exam prior to receiving
their first course of therapy (baseline) and then at 4, 11, and
39 days after the commencement of therapy. Conventional
T1-weighted and T2 fast spin echo (FSE) MRI were used to
identify and measure intrahepatic metastases and to objec-
tively quantify lesion responses to chemotherapy. Diffusion-
weighted imaging was used to monitor changes in the ADCw
of lesions. Imaging protocols were carried out on participants
in accordance with protocols approved by the IRB at the
University of Arizona. All MRIs were performed on a GE
Signa echospeed scanner at 1.5 T equipped with a 22-mT/m,
actively shielded, 120-mT/m per msec gradient system.
A single-shot fast spin echo (SSFSE) sequence was
utilized to obtain contiguous T2-weighted images within a
breath-hold encompassing the entire liver. Image parame-
ters for the T2-weighted images were: TE = 93.9 and 187
msec, 256  160 imagematrix, 0.5 signal averages (i.e., half-
Fourier), FOV = 36  27 cm, 31.3 kHz receiver bandwidth,
and 6 mm slice thickness. The use of the moderate and
heavily T2-weighted SSFSE scans enabled the differential
identification of cysts and hemangiomas by the radiologist
(E.O.) as described previously [25], and these lesions were
excluded from diffusion and LV measurements. T1- and T2-
weighted images were acquired within a breath-hold utilizing
a 3D fast gradient echo sequence. The 3D fast gradient echo
sequence obtained a 3D image of the abdomen, which
encompassed the whole liver. Image parameters for the 3D
T1-weighted images were: TE = 1.5 msec, TR = 7.2 msec,
256  128  32 image matrix, 6 mm slice thickness with no
interslice gap, FOV = 36  27 cm, and 62.5 kHz receiver
bandwidth. Images were transferred offline to a workstation
and viewed by a radiologist (E.O.), who manually circum-
scribed lesions in a blinded fashion.
Diffusion-Weighted Single-Shot Echo Planar Imaging
(SSEPI)
Diffusion-weighted SSEPI images were obtained through
the entire liver. Image parameters for the DW-SSEPI images
were as follows: TE = 103 msec, 128  90 image matrix,
FOV = 36  27 cm, TR = 6 seconds, 100 kHz receiver
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bandwidth, and 6 mm slice thickness. Diffusion-weighted
images were acquired during a breath-hold on inhalation in
6-mm slices through the entire liver. Diffusion weighting was
applied in the superior/inferior direction with b = 0, 150, 300,
450 sec/mm2. All measurements were repeated twice (i.e.,
two repetitions).
LV Measurements
Total tumor burden in the liver was determined by ana-
lyzing up to five of the largest tumor nodules in each patient.
Tumor nodule volumes were measured on the 3D fast
gradient echo images on contiguous slices. Manually circum-
scribed regions of interest (ROIs) were used to quantitate
the lesion area on each slice and these were multiplied by
the slice thickness and added-on contiguous slices to arrive
at LVs (mm3). Determination of lesion response was made
on a lesion-by-lesion basis by evaluating the ratio between
LVs on day 39 and pretherapy (i.e., day 3) LV (%DLV =
LVday 39 / LVbaseline).
ADCw Calculations
The influence of motion during acquisitions raised con-
cern regarding the accuracy of image registration from one
b value to the next. To overcome this, histograms of pixel
intensity were obtained for each lesion at each b value from
manually circumscribed ROIs combined across slices. Multi-
slice data and histograms were visualized using Amira image
analysis software (TGS, San Diego, CA). Average values of
signal intensity Ii were obtained from these histograms and
compared to the intensities in the absence of diffusion
weighting (Io), where b = 0. ADCw values were calculated
for each measurement using a least squares method to fit
a set of data points to ln(Ii/ Io) = biADCw (Eq. (1)), with the
y-intercept set equal to zero. Hence, an average ADCw value
was obtained for each lesion. In addition to intensity values,
pixel count values and intensity standard deviations were
obtained for each ROI at each repetition.
The changes in the ADCw values following therapy were
determined by calculating the percent change in the ADCw
from baseline (day 3), with each patient serving as his/her
own control. %ADCw
4, %ADCw
11, and %ADCw
39 correspond to
the percent change in the ADCw from baseline to days 4, 11,
and 39, respectively:
%ADC4w ¼
ADC4w  ADCbw
ADCbw
;
%ADC11w ¼
ADC11w  ADCbw
ADCbw
; ð1Þ
%ADC39w ¼
ADC39w  ADCbw
ADCbw
Results
Sixteen patients with metastatic breast cancer were initially
enrolled in this pilot trial. Three patients were unable to com-
plete the imaging protocol due to morbidity or early mortality.
Of the 13 evaluable patients, one patient was evaluated by
diffusion MRI during the initiation of two different courses
of chemotherapy (weekly paclitaxel and weekly vinorelbine).
Thus, the ability of diffusion MRI to accurately predict che-
motherapy responses was analyzed after the initiation of
14 separate chemotherapy regimens in 13 patients. Patient
characteristics as well as chemotherapy regimens received
during the study are detailed in Table 1. For the 13 evaluable
patients, up to five hepatic metastases were identified by
MRI for each patient, for a total of 60 lesions analyzed. All
patients were scanned at baseline, and then at 4, 11, and
39 days after commencement of a new chemotherapy reg-
imen. Diffusion imaging was not obtained on day 11 for
three patients. In addition, three lesions were not identifiable
on the day 39 diffusion-weighted images. Thus, 60 lesions
were analyzed for day 4, 50 lesions were analyzed for day
11, and 57 lesions were analyzed for day 39 (Table 2).
Examples of typical image quality are presented in
Figure 1, which shows echoplanar diffusion-weighted
images obtained at b values from 0 to 450 sec/mm2. At
higher b values, lesions have higher conspicuity relative to
normal liver, indicating motionally restricted water in the
lesion. Note also the presence of substructures within each
lesion, which may indicate microenvironmental hetero-
geneity. Because of visceral motion during the breath-hold
period, images at different b values were not parsed on a
pixel-by-pixel basis. This was determined early on in the
study where ADCw maps were calculated on a pixel-wise
basis using a single b value, according to ADCw(x,y) =
ln[I(x,y) / Io(x,y)] / b, where I is the intensity in the DW image
at b = 450 sec/mm2 and Io is the intensity in an image
obtained without diffusion gradients. Histograms of ADCw
pixel values were generated from tumor ROIs combined
across slices. From the ADCw histograms, a median value
was reported for each lesion and measurement. ADCw
values for the first and second measurements were labeled
by ADCw1 and ADCw2. The reproducibility of the ADCw value
was determined as the numeric difference between ADCw1
and ADCw2 for each lesion. These analyses showed a large
variability in the ADCw for lesions located in the dome of the
liver when analysis is done on a pixel-by-pixel basis, which
was likely due to cardiac motion (data not shown, provided
with review). The problem with pixel-by-pixel calculations
was also demonstrated with multiple b values, as shown in
Table 1. Patient Characteristics and Therapies.
Number of patients 13
Mean age (range) [years] 55 (38–73)
Female:male 12:1
Chemotherapy regimens
Taxane 9
Vinorelbine 3
Capecitabine 1
Paclitaxel and trastuzumab 1
Number of prior chemotherapy regimens
None 5
One 3
Two 3
z 3 2
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Figure 2. In these analyses, lesions were identified in whole
torso images (Figure 2A) and images were obtained at four
b values (Figure 2, B1–B4). Pixel-by-pixel fits to determine
the ADCw were obtained using Eq. (1), and the results are
displayed in Figure 2C, which shows a crescent of low ADCw
values near the ventral edge of the lesion. This region also
had low correlation coefficients (r2 < 0.85), further indicating
that this artifact was due to visceral motion (Figure 2D ).
Thus, to include all visible lesions with reliability, subsequent
analyses were performed with manually circumscribed ROIs
for each lesion at each b value.
As expected, there was a strong correlation, r = 0.977
(P < .001), between the manually circumscribed ROI pixel
counts (in DWMR images) and the LVs obtained from the
radiology reports, indicating that the circumscribed ROI
was an accurate representation of the LV (data not shown).
The average signal intensities within the ROIs were fit to
determine the ADCw using equation [1]. A summary of
lesion responses among the 13 patients is shown in Table
2. Although there appears to be a trend to smaller lesions
among the responding groups, this was not significant. This
was further documented by examining the relationship be-
tween the LVs at presentation (LVbaseline) and therapy-in-
duced change in LV (%DLV), shown in Figure 3. These data
clearly show no relationship between these two measures.
Mean intensity values were extracted from diffusion-
weighted images across all slices for each lesion at each
b value and each exam to calculate the ADCw. For the mean
ROI analysis, the numeric difference between ADCw1 and
ADCw2 was examined to determine reliability. Ideally, if a
measurement is reproducible, the difference should be
zero. The mean and the standard deviation of the difference
in the ADCw values obtained from the two replicated images
for each lesion and exam are 19.6 and 376.4 mm2/sec,
respectively. Patients were grouped from one to five accord-
ing to tumor response (Table 2). Because analysis was
completed on a lesion-by-lesion basis, there is a range of
tumor responses for each patient.
As stable or responding disease is similarly treated clin-
ically, the response groups were pooled into two larger
subsets. Lesions in groups 1 and 2 were considered non-
responders, and lesions in groups 3, 4, and 5 were pooled
into a responder subset. Figure 4 shows typical chances in
ADCw in a responding (right-hand panel) and a nonrespond-
ing (left-hand panel) patient. Data from all patients are
shown in Figure 5. These data indicate that, as a group, re-
sponders can be distinguished from nonresponders by day
11 following commencement of therapy. Table 3 indicates
that nonresponder ADCw values are never significantly dif-
ferent from baseline, whereas responders are significantly
different on days 11 and 39. Hence, an increase in the ADCw
value relative to baseline was a strong predictor of response.
The predictive value of the ADCw changes was also exam-
ined by constructing a receiver–operator–characteristic
(ROC) curve (Figure 6). As shown, there is significant
potential to diagnose response even by day 4, with an area
under the curve of 0.84, and this improves to 0.91 by day 11.
Sensitivity and specificity are both approximately 80% on
diagonal. Sensitivity can be over 70% at a specificity of 100%
and, conversely, a sensitivity of over 90% is reached at a
specificity of 70%. Sensitivity is TP / (TP + FN) and specificity
is TN / (TN + FP).
At a deeper level of evaluation, the strength of the
association between the ADCw and the objective clinical
response was evaluated using Pearson correlation coeffi-
cients. These compared the scalar clinical response (i.e.,
percent change in the LV between days3 and +39) with the
scalar percent change in ADCw. A significant correlation was
observed between tumor response and percent change in
ADCw at days 4 and 39, with the correlation on day 11 just
failing significance at a P value of .077 (Table 4). Negative
values of the Pearson coefficient indicated that the increases
in the ADCw were correlated to decreases in LVs. Notably,
the significance between tumor response and change in
Table 2. Summary of Lesion Responses.
Classification of Group
(%DLV = LV39 / LVB)
Lesion Counts Volumes at
Presentation
(cm3 ± SD)Baseline Day 4 Day 11 Day 39
1) Progressive disease
(>125%)
17 17 12 17 17.0 ± 43.4
2) Progressive disease
(113–125%)
4 4 2 4 94.5 ± 177.0
3) Stable (88–112%) 9 9 9 9 8.5 ± 10.3
4) Minor response
(75–87%)
6 6 6 6 7.4 ± 5.3
5) Major response
(< 74%)
24 24 21 21 10.8 ± 15.1
Figure 1. Representative images. Echoplanar diffusion-weighted images
from patient with breast cancer metastases. A full torso image is shown in the
lower left, wherein a metastatic lesion in the liver is delineated with circle. The
upper figures show the lesion images from the same slice obtained at b
values from 0 to 450 sec/mm2. In these images, the display gains have been
increased so as to scale to the brightest spot in each image. The actual
intensities decrease as shown in the plot. The natural log of the average
signal intensity within the ROI relative to b = 0 was expressed as a function of
b value to calculate the apparent diffusion coefficient ADCw (denoted as D in
the figure).
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ADCw held only for the smaller lesions (i.e., < 8 cm
3), even
though there was no difference in the overall response
rates between large and small lesions (Figure 3, Table 4).
It is also notable that the correlation was strongest on day
4, which was the earliest time point examined. This is
in contrast with the group analyses shown in Figure 5,
wherein the binary response/nonresponse was best pre-
dicted by day 11.
Discussion
A challenge to oncologists in the 21st century will be individ-
ualization of patient care. This will require minimally invasive
measures of patient response, preferably early in the ther-
apy regimen. The current pilot trial indicates that the MR-
measured ADCw may be appropriate as an early marker of
Figure 2. Pixel-by-pixel ADC calculations. Slice from torso image (A) was used to identify lesions, demarcated by circle. Lesion images were obtained at b values
from 0 to 450 sec/mm2 (B1–B4). Individual pixels were fit to obtain ADC values using Eq. (1), assuming perfect interimage registration. As above, the display gains
have been adjusted to the brightest spot in each image. This resulted in a dark crescent at the edge of the ADC map (C), suggesting misalignment of pixels
between scans at different b values. This was confirmed using a map of the correlation coefficients (D) wherein the bright values had higher r2 values (white > 0.90).
This map also showed that the dark crescent in (C) coregistered with the low r2 values in (D).
Figure 3. Relationship between pretherapy LV and clinical response. The
LV at presentation (LVbaseline) was determined manually by circumscribing
lesions on SSFSE images. The objective clinical response was determined
by calculating the change in LVs between presentation and day 39 follow-
ing commencement of therapy (%DLV). As shown, there is no correlation
between LV and response (r = 0.13).
Figure 4. Representative responses. Changes in the ADCw (o) and volumes
(.) for single lesions in a nonresponding patient and a responding patient.
ADCw values were calculated from ROI analyses, as described in the Mate-
rials and Methods section. LVs were calculated from SSFSE images obtained
in the same session. Data are expressed relative to the values at baseline.
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response in breast cancer patients with hepatic metastases.
This is in agreement with work from other groups who
have used ADCw to monitor response in brain tumors
[8,9,11,15,17]. The current work is different in that it is more
generally applicable to a larger number of patients, com-
pared to gliomas. Liver metastases are common for breast
carcinoma, gastrointestinal carcinoma, and melanoma. The
current results are apparently discrepant with a recent study
in rectal tumors, which showed a decrease in ADCw in
patients responding to chemoradiotherapy [27]. In that work,
the drop in ADCw was associated with a sloughing of dying
parts of the lesions into the lumen of the rectum. Hence,
the domains of the lesion that remained were not responding
and apparently healthy.
These results indicate that changes in the ADCw can
predict clinical outcome, within limits. First, the pooled data
suggest that statistical significance is highest by day 11,
compared to day 4. This is in contrast to the correlation
analyses, which showed a higher significance at day 4. This
apparent discrepancy could be explained by the presence of
two outliers in the responding group on day 4, thus reducing
the average change by day 4. These outliers were both
larger (> 8 cm3) lesions, and the correlation coefficients for
this group of lesions were reduced. Pearson correlation
coefficients are sensitive to outliers. All of these analyses
suggest that smaller tumors respond more quickly and,
consequently, the optimum time for evaluation may be
dependent on the size of the lesions. Despite this, significant
data were obtained from smaller lesions, even though they
are more difficult to circumscribe and more prone to process-
ing errors.
A shortcoming of the current work is in the inability to
assess microdomain structure by parsing the data on a pixel-
by-pixel basis due to visceral motion between scans. Hence,
data analyses required cumbersome, manual circumscribing
of ROI. We are currently working on solutions for automated
segmentation and registration of these lesions. Pixel-by-
pixel analyses will also allow interrogation of the geo-
graphic microdomains of lesion ADCw values (e.g., Figure 1),
which may yield higher dynamic range and higher density
Figure 5. Distribution of ADCw values for nonresponders and responders and
volumes. Patients with positive responses or stable disease (classes 3–5)
were grouped as responders (o), and those in classes 1 and 2 were grouped
as nonresponders (.). Data show ADCw values (± SD) normalized to the
individual pretherapy baseline ADCw for each patient. Data points are shown
for baseline, day 4 (P = .312), day 11 (P = .066), and day 39 (P = .074).
Table 3. F and P Values from Paired ANOVA Test Comparing Patient ADC
Values on Days 4, 11, and 39 Following Commencement of Therapy Versus
Their Baseline Values.
Nonresponders
(Categories 1 and 2)
Responders/Stable
(Categories 3–5)
F P F P
Day 4 vs day 0 1.682 0.20 0.292 0.590
Day 11 vs day 0 1.013 0.32 5.610 0.021
Day 39 vs day 0 0.279 0.60 7.379 0.008
Figure 6. ROC curves. ROC for day 4 (.) and day 11 (o) posttherapy.
Lesions were identified as responders or nonresponders, and the changes in
ADCw were rank-ordered. At each value of percent change in ADCw, the
numbers of responders at higher values were classified as true positives (TP)
and the number of nonresponders were false positives (FP). At all lower
values, the numbers of nonresponders at lower values were true negatives
(TN) and the numbers of responders were false negatives (FN). The areas
under the curve for each analysis were 0.84 on day 4 and 0.91 on day 11.
Table 4. Pearson Correlation Values for All Lesions on Days 4, 11, and 39
Postcommencement of Chemotherapy.
Day Test Lesions
All < 8 cm3 > 8 cm3
4 Pearson correlation 0.305 0.413 0.140
P (two-tailed) 0.018 0.008 0.557
N 60 40 20
11 Pearson correlation 0.253 0.306 0.215
P (two-tailed) 0.077 0.069 0.416
N 50 36 14
39 Pearson correlation 0.285 0.345 0.212
P (two-tailed) 0.032 0.032 0.397
N 57 39 18
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of relevant information. We hypothesize that such data will
have greater sensitivity than the current ROI analysis.
Changes in the ADCw are presumably distal to the site
of drug action. Hence, it is more appropriate as a biomarker
for clinical response than, for example, detection of phar-
macodynamics. This distinguishes it from more directed
molecular imaging approaches to measure drug– target
interactions. It is also distinguished from positron emission
tomography imaging of fluorodeoxyglucose (FdG-PET) trap-
ping. Changes in FdG uptake and retention can be observed
with tumor response. Because FdG-PET requires delivery of
substrate to cells, specific uptake rates are affected by the
rate and flow of delivery (i.e., vascular changes), metabolism
(i.e., changes in monosaccharide transport or phosphoryl-
ation), or cell number. Despite these ambiguities, changes in
FdG trapping can be very sensitive and more proximal to the
site of drug action. In contrast, diffusion MRI is more distal
from the drug, but possibly more connected with ultimate
response. Hence, in a clinical setting, it may be used to
quantitatively detect and predict outcome in individual
patients.
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